Cargando…

P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL

Detalles Bibliográficos
Autores principales:	Bahlis, Nizar J, Trudel, Suzanne, Quach, Hang, Popat, Rakesh, Lonial, Sagar, Orlowski, Robert Z, Kim, Kihyun, Mateos, Maria-Victoria, Pawlyn, Charlotte, Ramasamy, Karthik, Martinez-Lopez, Joaquín, Casas-Avilés, Ignacio, Spirli, Alessia, Gong, Jing, Amatangelo, Michael, Katz, Jessica, Maciag, Paulo, Peluso, Teresa, Richardson, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430921/ http://dx.doi.org/10.1097/01.HS9.0000970376.71405.63

Ejemplares similares

Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC‐92480), a novel cereblon E3 ligase modulator
por: Wu, Fan, et al.
Publicado: (2023)

S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS
por: Bahlis, Nizar J, et al.
Publicado: (2023)

P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY
por: Schjesvold, F, et al.
Publicado: (2023)

Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM
por: Jeryczynski, Georg, et al.
Publicado: (2021)

S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
por: Lonial, Sagar, et al.
Publicado: (2021)

P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1
por: Rasche, Leo, et al.
Publicado: (2023)

P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL
por: Amatangelo, M., et al.
Publicado: (2022)

Fungal Planet description sheets: 868–950
por: Crous, P.W., et al.
Publicado: (2019)

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY
por: Suvannasankha, A., et al.
Publicado: (2022)

DEX, Delirium and Dilemma
por: Magoon, Rohan, et al.
Publicado: (2023)

Daily Changes in Channel Occupancy in the 868 MHz ISM Band
por: Kozłowski, Sebastian, et al.
Publicado: (2022)

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD) IN THE DREAMM-3 STUDY
por: Hungria, Vania, et al.
Publicado: (2023)

P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.
por: Vesole, David H., et al.
Publicado: (2023)

Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients
por: Martín-Sánchez, Esperanza, et al.
Publicado: (2021)

Channel Occupancy Measurements in 868 MHz ISM Band in Residential Areas
por: Kozłowski, Sebastian, et al.
Publicado: (2021)

Edition Eulenburg No. 868, Op. 325 : Geschichten aus dem Wiener Wald Tales of the Vienna Forest Histoires de la Forêt de Vienne /

Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023
por: Mateos, Maria-Victoria, et al.
Publicado: (2015)

Synergistic Effect of Perineural Dexamethasone and Dexmedetomidine (Dex-Dex) Prolong Analgesic Effect of a Preoperative Interscalene Block
por: Noor, Nazir A, et al.
Publicado: (2020)

868. Investigations of Healthcare-Associated Elizabethkingia Infections – United States, 2013-2019
por: Crist, Matthew B, et al.
Publicado: (2020)

Synergistic Effect of Perineural Dexamethasone and Dexmedetomidine (Dex-Dex) in Extending the Analgesic Duration of Pectoral Type I and II Blocks
por: Zusman, Robert P, et al.
Publicado: (2020)

Correction: Synergistic Effect of Perineural Dexamethasone and Dexmedetomidine (Dex-Dex) Prolong Analgesic Effect of a Preoperative Interscalene Block
por: Noor, Nazir A, et al.
Publicado: (2020)

Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM
por: Park, Hyunkyung, et al.
Publicado: (2022)

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS
por: Mateos, M, et al.
Publicado: (2022)

The Italian scenario, pts 1-2
por: Belloni, L
Publicado: (1987)

PTS: a pharmaceutical target seeker
por: Ding, Peng, et al.
Publicado: (2017)

P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T-CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST-IN-HUMAN CLINICAL STUDY
por: Wong, Sandy W., et al.
Publicado: (2023)

P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Sidana, Surbhi, et al.
Publicado: (2023)

Run 868 - 26.8.77, Short term vacuum limit test in ring 2
por: Fischer, E, et al.
Publicado: (1977)

Draft genome of Paraburkholderia fungorum sequence type 868 recovered from human synovial tissues
por: Loong, Shih Keng, et al.
Publicado: (2019)

868. Prospective Pathogen Detection in Patients With Central Nervous System Inflammation Using Metagenomic Sequencing
por: Piantadosi, Anne, et al.
Publicado: (2018)

POS-868 THE USE OF OXIRIS MEMBRANE IN CRITICAL ILL PATIENTS WITH SARS COV-2 PNEUMONIA
por: Rizo Topete MD, L., et al.
Publicado: (2022)

LoRa, Zigbee and 5G Propagation and Transmission Performance in an Indoor Environment at 868 MHz
por: Robles-Enciso, Ricardo, et al.
Publicado: (2023)

PB2703: ISA-KD IN NOT TRANSPLANT CANDIDATES RRMM. EXPERIENCE IN REAL LIFE.
por: Llorente, Dunia De Miguel, et al.
Publicado: (2023)

868. HIV, Opioid Use Disorder, and Injection related Infections: Clinical Outcomes in 4 Academic Hospitals
por: Bassler, John R, et al.
Publicado: (2021)

DC Power Line Communication (PLC) on 868 MHz and 2.4 GHz Wired RF Transceivers
por: Marsic, Vlad, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa
por: Yi, B. Alexander, et al.
Publicado: (2021)

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lonial, Sagar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ar3takmsvg36v6m127miihsaq2